Zofenopril
From Wikipedia, the free encyclopedia
Zofenopril
|
|
Systematic (IUPAC) name | |
(2S,4S)-1-[(2S)-3-(Benzoylsulfanyl)-2-methylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid | |
Identifiers | |
CAS number | |
ATC code | C09 |
PubChem | |
Chemical data | |
Formula | C22H23NO4S2 |
Mol. mass | 429.552 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Oral |
Zofenopril (also known as Zofenoprilum [Latin]) is an angiotensin converting enzyme (ACE) inhibitor with cardioprotective properties indicated for the treatment of hypertension.[1]
In small studies, zofenopril appeared significantly more effective than the older antihypertensives atenolol and enalapril, and was associated with less adverse effects.[2][3]
[edit] References
- ^ Ambrosioni E (2007). "Defining the role of zofenopril in the management of hypertension and ischemic heart disorders". Am J Cardiovasc Drugs 7 (1): 17–24. PMID 17355163.
- ^ Nilsson P (October 2007). "Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension". Blood Press Suppl 2: 25–30. PMID 18046976.
- ^ Mallion JM (October 2007). "An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension". Blood Press Suppl 2: 13–8. PMID 18046974.
|